or Try an Advanced Search...

    Technical Analysis for KRON - Kronos Bio, Inc.

    Grade Last Price % Change Price Change
    F 1.05 0.96% 0.01
    KRON closed down 0.95 percent on Wednesday, May 8, 2024, on 53 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Up
    Historical KRON trend table...
    Date Alert Name Type % Chg
    Shooting Star Candlestick Bearish 0.96%
    Lizard Bearish Bearish Day Trade Setup 0.96%
    20 DMA Support Bullish 0.96%
    NR7 Range Contraction 0.96%
    Earnings Movers Other 0.96%
    Gapped Down Weakness 0.96%
    Crossed Above 20 DMA Bullish 0.00%
    20 DMA Resistance Bearish 1.94%
    20 DMA Resistance Bearish 2.94%
    20 DMA Resistance Bearish 1.94%
    Older End-of-Day Signals for KRON ...

       Recent Intraday Alerts

    Alert Time
    Gap Up Closed 36 minutes ago
    60 Minute Opening Range Breakdown about 2 hours ago
    2x Volume Pace about 5 hours ago
    1.5x Volume Pace about 5 hours ago
    Gap Up Partially Closed about 5 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    KRON Chart by TradingView
    Basic chart:

    Profile

    Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib, a selective inhibitor targeting spleen tyrosine kinase in acute myeloid leukemia patients. The company is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors. Kronos Bio, Inc. is founded in 2017 and is headquartered in San Mateo, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Biology Solid Tumors Acute Myeloid Leukemia Enzymes Tyrosine Kinase Transcription Transcription Factors Cancer Therapeutics Novel Cancer Transcription Factor Cyclin Dependent Kinase Entospletinib Morpholines

    Is KRON a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 6 Kronos Bio: Underestimated Drug Discovery Platform
    May 6 Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates
    Apr 24 Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    Mar 27 Kronos Bio (KRON) Upgraded to Buy: What Does It Mean for the Stock?
    Mar 21 Kronos Bio reports Q4 results
    Mar 21 Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results
    Mar 7 Kronos cuts 21% of workforce, extends cash runway into 2H 2026
    Mar 7 Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway
    Mar 5 Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting
    Feb 27 Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference
    See more KRON news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 2.29
    52 Week Low 0.731
    Average Volume 470,578
    200-Day Moving Average 1.20
    50-Day Moving Average 1.13
    20-Day Moving Average 1.03
    10-Day Moving Average 1.02
    Average True Range 0.08
    RSI (14) 46.24
    ADX 23.54
    +DI 10.60
    -DI 17.84
    Chandelier Exit (Long, 3 ATRs) 0.98
    Chandelier Exit (Short, 3 ATRs) 1.13
    Upper Bollinger Bands 1.14
    Lower Bollinger Band 0.93
    Percent B (%b) 0.54
    BandWidth 20.71
    MACD Line -0.03
    MACD Signal Line -0.04
    MACD Histogram 0.009
    Fundamentals Value
    Market Cap 60.65 Million
    Num Shares 58.3 Million
    EPS -2.08
    Price-to-Earnings (P/E) Ratio -0.50
    Price-to-Sales 15.45
    Price-to-Book 0.35
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.10
    Resistance 3 (R3) 1.10 1.09 1.09
    Resistance 2 (R2) 1.09 1.07 1.09 1.09
    Resistance 1 (R1) 1.06 1.06 1.08 1.06 1.08
    Pivot Point 1.05 1.05 1.05 1.05 1.05
    Support 1 (S1) 1.02 1.03 1.04 1.02 1.00
    Support 2 (S2) 1.01 1.02 1.01 0.99
    Support 3 (S3) 0.98 1.01 0.99
    Support 4 (S4) 0.98